Depressive SymptomsNCT04444713
Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?
An observational study of Depressive Symptoms and Metacognitive Variables, run by Modum Bad.
Trial summary
The aim of the study is to identify symptom-level intervention targets for depression related to the COVID-19 outbreak. First, we will assess centrality indices of the network of depression symptoms plus mechanism variables derived from the metacognitive model of psychopathology measured at a period of strict social… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Depressive Symptoms, Metacognitive Variables
- How many people
- 10,084 participants
- Where
- No sites listed yet
- Study dates
- 22 Jun 2020to 13 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Eligible participants are all individuals of 18 years and above, who are living in Norway and thus experience identical distancing protocols, and who provide informed consent to participate in the study. For this study, only participants reaching the cut-off value (>= 5; Kroenke et al, 2001) for subclinical symptoms on the PHQ-9 at T1 will be approached for a second measurement (T2), amounting to 6 508 individuals.
Who may be able to join
- all adults residing in Norway during the government-initiated interventions for the COVID-19 pandemia
Who cannot join
- none
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Centrality in the Cross-sectional Network of Depressive Symptom and Metacognitive Variables During COVID-19: Do Central Variables Predict Overall Symptom Reduction From Periods of Strict to Lifted Social Distancing Protocols?
The aim of the study is to identify symptom-level intervention targets for depression related to the COVID-19 outbreak. First, we will assess centrality indices of the network of depression symptoms plus mechanism variables derived from the metacognitive model of psychopathology measured at a period of strict social distancing protocols (T1). Then, we will examine whether change in the most central symptom and metacognitive variables are more related to overall symptom reduction from the period of strict (T1) to a period of lifted social distancing protocols (T2) three months later. On the basis of the results, interventions can be suggested that protect the general public against increased psychological suffering and dysfunction during society's handling of pandemics.
Read the detailed description
Hypotheses (Hs) H1: In the cross-sectional depression-metacognitive network at T1, the symptoms depressed mood, little interest/pleasure, and self-blame and the metacognitive coping variables rumination/worry, threat monitoring, situational avoidance, thought suppression, and uncontrollability of thoughts will be the most central variables.
H2: Reductions of the most central variables of the cross-sectional network from T1 to T2 will be more related to overall reduction of symptoms in the same time frame than reductions of the less central variables.
Study design and participants The design is a longitudinal observational survey of the general adult Norwegian population during the COVID-19 pandemic. Eligible participants are all individuals of 18 years and above, who are living in Norway and thus experience identical distancing protocols, and who provide informed consent to participate in the study. For this study, only participants reaching the cut-off value (>= 5; Kroenke et al, 2001) for subclinical symptoms on the PHQ-9 at T1 will be included, amounting to 6 508 individuals. The strict social distancing protocols were implemented in Norway at March 12. 2020 and the first data collection in this period (T1) has already been done. It lasted seven days and was between March 31st 2020 and April 7th 2020. Thus, the strict protocols had been held constant during the two weeks prior to data collection, as well as during the data collection week. Furthermore, no new information was given by the government during this period with regard to changes of distancing protocols, keeping expectation effects constant. From June 15., the majority of the distancing protocols will be lifted in Norway, and the T2 period is defined from this date. Data are set to be collected from the sample providing data in the first collection (N = 10 084), starting one week after the lifting of the protocols, that is, from 22th of June. The collection will last until enough data has been collected, but no longer than three weeks.
Ethical approval of the study was granted by The Regional Committee for Medical and Health Research Ethics and the Norwegian Centre for Research Data (reference numbers: 125510 and 802810, respectively, for the first data collection, and , respectively for the second data collection), where the study protocol and analysis plan was approved prior to data collection. The study is conducted in accordance with the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology statement (STROBE; Von Elm et al., 2007). The pre-registered protocol for a study of loneliness based on the first (T1) data collection can be found at Clinicaltrials.gov (Identifier: NCT04365881). The study is part of The Norwegian COVID-19, Mental Health and Adherence Project (Ebrahimi, Hoffart, \& Johnson, 2020).
Procedures The survey is disseminated online. At T1, it was disseminated in a systematic manner to give the adult population an equal opportunity to participate in the study. The dissemination procedure involved information about the survey through broadcasting on national, regional, and local news channels and provision of the online survey to a random selection of Norwegian adults on Facebook. The dissemination procedure is described in detail elsewhere (Ebrahimi et al., 2020).
The stopping rule for the first data collection was designed to ensure that the SDPs were held constant for two weeks prior to and the week during the data collection period, as well as controlling for expectation effects by stopping data collection instantly once information concerning forthcoming modification of the social distancing protocols were given. The second data collection - approaching the 10 084 individuals of the first collection - will start one week after the strict protocols are lifted (June 22.) and last three weeks.
Sample size and power The sample providing data at T1 comprised 10 084 participants, ascertaining power for the questions asked. All these participants will be invited to partake in the second data collection during the lifted prptocols period (T2) in accordance with the study plan. The mentioned 'Norwegian COVID-19, Mental Health and Adherence Project' involves multiple studies, where some involve a Complex Systems (Network analysis) approach. These mutlivariate analyses require large samples and power analysis was conducted accordingly. Following power analysis guidelines by Fried \& Cramer (2017), it is recommended that the number of participants be at the very least three times larger than the number of estimated parameters. However, more conservative recommendations by Roscoe (1975) for multivariate research, recommends sample size that is ten times larger than the number of estimated parameters. For our network of 9 PHQ-9 variables and 16 CAS-1 variables, the number of edges in the network is 25*24/2 = 300. Thus, according to the conservative advice of Roscoe, the required sample size is 3 000.
Blinding No blinding is involved in this study.
Is there any additional blinding in this study? Not applicable
Randomization No randomization.
Sampling Plan
Existing Data Registration prior to the analysis of the T1 data and prior to the collection of the T2 data.
Explanation of existing data The pandemics (and the consequent social distancing protocols) occurred, by its very nature, unexpectedly and the project could not be planned in advance. Thus, the first data collection started immediately and before pre-registration. It started during the time-period with the strictest protocols in Norway, and the first data collection was stopped before these protocols were modified or new information about them were added. We have avoided any network analysis of the data.
Manipulated variables Not applicable/NA
Statistical analysis To test H1, the network of the 9 PHQ items and the 16 CAS-1 items will be estimated using the R package qgraph (Epskamp et al., 2012) in a random half of the sample. Network stability tests will be conducted using R package bootnet (Epskamp, et al., 2018). An undirected partial correlation network will be estimated, resulting in associations between each pair of symptoms controlling for all other associations among symptoms. Centrality indices - strength and betweenness - will be computed according to the method of Robinaugh et al. (2016). Strength refers to how strongly a node relates to other nodes. Betweenness refers to how important a node is in paths between other nodes. Hypothesis 2 will be tested in the other random half of the sample. The outcomes of interest will be the degree to which change in a variable from T1 to T2 correlates with the change in the PHQ-9 total score (minus the variable examined if it is a symptom).
Missing data There are no missing data in the first data collection because the survey includes only mandatory responses. Dropout from the second data collection is to be expected, but the amount of missing data is uncertain. The multiple imputation procedure in SPSS will be used to impute missing data.
Exploratory analysis We may do other exploratory analysis that we have not yet thought of at the time of preregistration. If we do such exploratory analyses, we will explicitly state them as exploratory in the published manuscript following common publishing guidelines.
Other The data include one directly identifiable variable (contact information) for participants in accordance to the General Data Protection Regulation (GDPR) law in EU, which is to give the participants the opportunity to have their data deleted upon request. Data are thus kept on a safe server belonging to the University of Oslo and will be accessed first following de-identification.
- Conditions
- Depressive Symptoms, Metacognitive Variables
- Medical subject headings
- Depression
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, \& Williams, 2001) consists of nine items covering the DSM-IV criteria for major depression scored on a four-point 0 (not at all) to 3 (almost every day) scale, with total scores ranging from 0 to 27. The PHQ-9 has revealed good psychometric properties, as demonstrated by Kroenke, Spitzer, and Williams (2001).
Measured: From 22nd of June to 13th of July
Cognitive-Attentional Syndrome-1 (CAS-1)
The Cognitive Attentional Syndrome-1 (CAS-1; Wells, 2009) measures maladaptive mental and behavioral coping with thoughts and feelings (8 items, 0-8 scales) and negative and positive metacognitions (8 items, 0-100 scales). The CAS-1 has proved to have satisfactory psychometric properties (Nordahl \& Wells, 2019).
Measured: From 22nd of June to 13th of July
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2020
- Study start22 Jun 2020 (estimated)
- Primary completion13 Jul 2020 (estimated)
- Study completion13 Jul 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depressive SymptomsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 10,084 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Modum Bad
- Sponsor type
- University, hospital or other
- Collaborators
- University of Oslo
- Responsible party
- Principal investigator, Asle Hoffart, Modum Bad
- Investigators
- Asle Hoffart, PhD, Principal investigator, University of Oslo and Modum BadOmid Ebrahimi, CandPsychol, Principal investigator, Modum Bad and University of OsloSverre Urnes Johnson, PhD, Principal investigator, University of Oslo and Modum Bad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04444713
- Sponsor's protocol ID
- 802810-2
- Status last verified
- Jun 2020
- First submitted
- 20 Jun 2020
- Last updated
- 23 Jun 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Centrality in the Cross-sectional Network of Depressive Symptom and Metacognitive Variables During COVID-19: Do Central Variables Predict Overall Symptom Reduction From Periods of Strict to Lifted Social Distancing Protocols?
- ClinicalTrials.gov ID
- NCT04444713
- Acronym / sponsor ID
- 802810-2
- Conditions
- Depressive Symptoms, Metacognitive Variables
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,084 participants (estimated)
- Lead sponsor
- Modum BadUniversity, hospital or other
- Collaborators
- University of Oslo
- Study start
- 22 Jun 2020 (estimated)
- Primary completion
- 13 Jul 2020 (estimated)
- Study completion
- 13 Jul 2020 (estimated)
- First posted
- 23 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to identify symptom-level intervention targets for depression related to the COVID-19 outbreak. First, we will assess centrality indices of the network of depression symptoms plus mechanism variables derived from the metacognitive model of psychopathology measured at a period of strict social distancing protocols (T1). Then, we will examine whether change in the most central symptom and metacognitive variables are more related to overall symptom reduction from the period of strict (T1) to a period of lifted social distancing protocols (T2) three months later. On the basis of the results, interventions can be suggested that protect the general public against increased psychological suffering and dysfunction during society's handling of pandemics.
Detailed description
Hypotheses (Hs) H1: In the cross-sectional depression-metacognitive network at T1, the symptoms depressed mood, little interest/pleasure, and self-blame and the metacognitive coping variables rumination/worry, threat monitoring, situational avoidance, thought suppression, and uncontrollability of thoughts will be the most central variables.
H2: Reductions of the most central variables of the cross-sectional network from T1 to T2 will be more related to overall reduction of symptoms in the same time frame than reductions of the less central variables.
Study design and participants The design is a longitudinal observational survey of the general adult Norwegian population during the COVID-19 pandemic. Eligible participants are all individuals of 18 years and above, who are living in Norway and thus experience identical distancing protocols, and who provide informed consent to participate in the study. For this study, only participants reaching the cut-off value (>= 5; Kroenke et al, 2001) for subclinical symptoms on the PHQ-9 at T1 will be included, amounting to 6 508 individuals. The strict social distancing protocols were implemented in Norway at March 12. 2020 and the first data collection in this period (T1) has already been done. It lasted seven days and was between March 31st 2020 and April 7th 2020. Thus, the strict protocols had been held constant during the two weeks prior to data collection, as well as during the data collection week. Furthermore, no new information was given by the government during this period with regard to changes of distancing protocols, keeping expectation effects constant. From June 15., the majority of the distancing protocols will be lifted in Norway, and the T2 period is defined from this date. Data are set to be collected from the sample providing data in the first collection (N = 10 084), starting one week after the lifting of the protocols, that is, from 22th of June. The collection will last until enough data has been collected, but no longer than three weeks.
Ethical approval of the study was granted by The Regional Committee for Medical and Health Research Ethics and the Norwegian Centre for Research Data (reference numbers: 125510 and 802810, respectively, for the first data collection, and , respectively for the second data collection), where the study protocol and analysis plan was approved prior to data collection. The study is conducted in accordance with the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology statement (STROBE; Von Elm et al., 2007). The pre-registered protocol for a study of loneliness based on the first (T1) data collection can be found at Clinicaltrials.gov (Identifier: NCT04365881). The study is part of The Norwegian COVID-19, Mental Health and Adherence Project (Ebrahimi, Hoffart, \& Johnson, 2020).
Procedures The survey is disseminated online. At T1, it was disseminated in a systematic manner to give the adult population an equal opportunity to participate in the study. The dissemination procedure involved information about the survey through broadcasting on national, regional, and local news channels and provision of the online survey to a random selection of Norwegian adults on Facebook. The dissemination procedure is described in detail elsewhere (Ebrahimi et al., 2020).
The stopping rule for the first data collection was designed to ensure that the SDPs were held constant for two weeks prior to and the week during the data collection period, as well as controlling for expectation effects by stopping data collection instantly once information concerning forthcoming modification of the social distancing protocols were given. The second data collection - approaching the 10 084 individuals of the first collection - will start one week after the strict protocols are lifted (June 22.) and last three weeks.
Sample size and power The sample providing data at T1 comprised 10 084 participants, ascertaining power for the questions asked. All these participants will be invited to partake in the second data collection during the lifted prptocols period (T2) in accordance with the study plan. The mentioned 'Norwegian COVID-19, Mental Health and Adherence Project' involves multiple studies, where some involve a Complex Systems (Network analysis) approach. These mutlivariate analyses require large samples and power analysis was conducted accordingly. Following power analysis guidelines by Fried \& Cramer (2017), it is recommended that the number of participants be at the very least three times larger than the number of estimated parameters. However, more conservative recommendations by Roscoe (1975) for multivariate research, recommends sample size that is ten times larger than the number of estimated parameters. For our network of 9 PHQ-9 variables and 16 CAS-1 variables, the number of edges in the network is 25*24/2 = 300. Thus, according to the conservative advice of Roscoe, the required sample size is 3 000.
Blinding No blinding is involved in this study.
Is there any additional blinding in this study? Not applicable
Randomization No randomization.
Sampling Plan
Existing Data Registration prior to the analysis of the T1 data and prior to the collection of the T2 data.
Explanation of existing data The pandemics (and the consequent social distancing protocols) occurred, by its very nature, unexpectedly and the project could not be planned in advance. Thus, the first data collection started immediately and before pre-registration. It started during the time-period with the strictest protocols in Norway, and the first data collection was stopped before these protocols were modified or new information about them were added. We have avoided any network analysis of the data.
Manipulated variables Not applicable/NA
Statistical analysis To test H1, the network of the 9 PHQ items and the 16 CAS-1 items will be estimated using the R package qgraph (Epskamp et al., 2012) in a random half of the sample. Network stability tests will be conducted using R package bootnet (Epskamp, et al., 2018). An undirected partial correlation network will be estimated, resulting in associations between each pair of symptoms controlling for all other associations among symptoms. Centrality indices - strength and betweenness - will be computed according to the method of Robinaugh et al. (2016). Strength refers to how strongly a node relates to other nodes. Betweenness refers to how important a node is in paths between other nodes. Hypothesis 2 will be tested in the other random half of the sample. The outcomes of interest will be the degree to which change in a variable from T1 to T2 correlates with the change in the PHQ-9 total score (minus the variable examined if it is a symptom).
Missing data There are no missing data in the first data collection because the survey includes only mandatory responses. Dropout from the second data collection is to be expected, but the amount of missing data is uncertain. The multiple imputation procedure in SPSS will be used to impute missing data.
Exploratory analysis We may do other exploratory analysis that we have not yet thought of at the time of preregistration. If we do such exploratory analyses, we will explicitly state them as exploratory in the published manuscript following common publishing guidelines.
Other The data include one directly identifiable variable (contact information) for participants in accordance to the General Data Protection Regulation (GDPR) law in EU, which is to give the participants the opportunity to have their data deleted upon request. Data are thus kept on a safe server belonging to the University of Oslo and will be accessed first following de-identification.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Eligible participants are all individuals of 18 years and above, who are living in Norway and thus experience identical distancing protocols, and who provide informed consent to participate in the study. For this study, only participants reaching the cut-off value (>= 5; Kroenke et al, 2001) for subclinical symptoms on the PHQ-9 at T1 will be approached for a second measurement (T2), amounting to 6 508 individuals.
Key inclusion criteria (1 listed)
- all adults residing in Norway during the government-initiated interventions for the COVID-19 pandemia
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient Health Questionnaire-9 (PHQ-9)
Time frame: From 22nd of June to 13th of July
The Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, \& Williams, 2001) consists of nine items covering the DSM-IV criteria for major depression scored on a four-point 0 (not at all) to 3 (almost every day) scale, with total scores ranging from 0 to 27. The PHQ-9 has revealed good psychometric properties, as demonstrated by Kroenke, Spitzer, and Williams (2001).
Cognitive-Attentional Syndrome-1 (CAS-1)
Time frame: From 22nd of June to 13th of July
The Cognitive Attentional Syndrome-1 (CAS-1; Wells, 2009) measures maladaptive mental and behavioral coping with thoughts and feelings (8 items, 0-8 scales) and negative and positive metacognitions (8 items, 0-100 scales). The CAS-1 has proved to have satisfactory psychometric properties (Nordahl \& Wells, 2019).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2020.
Related trials for Depressive Symptoms
Recruiting
Cancer Pain Management Using a Web-based Intervention
Cancer of Breast, Depressive Symptoms
Active, not recruiting
Improving Student Mental Health Through a Universal Trauma-Informed Intervention
Anxiety Symptoms, Post-traumatic Stress Symptoms
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asle Hoffart, PhD principal investigator
University of Oslo and Modum Bad
Omid Ebrahimi, CandPsychol principal investigator
Modum Bad and University of Oslo
Sverre Urnes Johnson, PhD principal investigator
University of Oslo and Modum Bad
Questions about this trial
What is this clinical trial studying?
An observational study of Depressive Symptoms and Metacognitive Variables, run by Modum Bad.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Asle Hoffart, PhD (+4790594733, asle.hoffart@modum-bad.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Health Questionnaire-9 (PHQ-9) (time frame: From 22nd of June to 13th of July). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2020.